A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8+T Cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Maji, Mithun ^a   Mazumder, Saumyabrata ^a,b   Bhattacharya, Souparno ^a,c   Choudhury, Somsubhra Thakur ^a   Sabur, Abdus ^a   Shadab, Md ^a   Bhattacharya, Pradyot ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Premas Biotech Pvt Ltd   (India)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP63, LEISHMANIA; HLA ANTIGEN CLASS 1; IMMUNOLOGICAL ADJUVANT; LIPOSOME; METALLOPROTEINASE; RECOMBINANT PROTEIN;

ANIMAL; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DENDRITIC CELL; DRUG EFFECT; FEMALE; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; LIPOSOMES; METALLOENDOPEPTIDASES; MICE; RECOMBINANT PROTEINS;

EID: 84973340093     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27206     Document Type: Article

References (60)

1. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1, 362-368 (1999).
2. Ackerman, A. L., Kyritsis, C., Tampe, R. & Cresswell, P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 100, 12889-12894 (2003).
3. Tanaka, Y., Taneichi, M., Kasai, M., Kakiuchi, T. & Uchida, T. Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS One 5, e15225 (2010).
4. Agger, E. M. et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3, e3116 (2008).
5. Jain, K. & Jain, N. K. Vaccines for visceral leishmaniasis: A review. J Immunol Methods 422, 1-12 (2015).
6. Flatz, L. et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16, 339-345 (2010).
7. Brave, A., Ljungberg, K., Wahren, B. & Liu, M. A. Vaccine delivery methods using viral vectors. Mol Pharm 4, 18-32 (2007).
8. Plotkin, S. A. Vaccines: past, present and future. Nat Med 11, S5-11 (2005).
9. Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. Nature 462, 449-460 (2009).
10. Sexton, A. et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 3, 3391-3400 (2009).
11. Trumpfheller, C. et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271, 183-192 (2012).
12. Nordly, P., Agger, E. M., Andersen, P., Nielsen, H. M. & Foged, C. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res 28, 553-562 (2011).
13. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 10, 243-251 (2011).
14. Kataoka, K., Harada, A. & Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47, 113-131 (2001).
15. Mazumder, S., Maji, M. & Ali, N. Potentiating Effects of MPL on DSPC Bearing Cationic Liposomes Promote Recombinant GP63 Vaccine Efficacy: High Immunogenicity and Protection. Plos Neglected Tropical Diseases 5, doi: 10.1371/journal.pntd.0001429 (2011).
16. Joshi, M. D., Unger, W. J., Storm, G., van Kooyk, Y. & Mastrobattista, E. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 161, 25-37 (2012).
17. Smith, D. M., Simon, J. K. & Baker, J. R., Jr. Applications of nanotechnology for immunology. Nat Rev Immunol 13, 592-605 (2013).
18. Krishnan, L., Sad, S., Patel, G. B. & Sprott, G. D. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 63, 2526-2534 (2003).
19. Krishnan, L., Sad, S., Patel, G. B. & Sprott, G. D. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J Immunol 166, 1885-1893 (2001).
20. Schwendener, R. A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2, 159-182 (2014).
21. Davidsen, J. et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718, 22-31 (2005).
22. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4, 145-160 (2005).
23. Korsholm, K. S., Andersen, P. L. & Christensen, D. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status. Expert Rev Vaccines 11, 561-577 (2012).
24. Pashine, A., Valiante, N. M. & Ulmer, J. B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11, S63-68 (2005).
25. Casella, C. R. & Mitchell, T. C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65, 3231-3240 (2008).
26. Ravindran, R., Maji, M. & Ali, N. Vaccination with Liposomal Leishmanial Antigens Adjuvanted with Monophosphoryl Lipid-Trehalose Dicorynomycolate (MPL-TDM) Confers Long-Term Protection against Visceral Leishmaniasis through a Human Administrable Route. Molecular Pharmaceutics 9, 59-70 (2012).
27. Hafez, I. M., Maurer, N. & Cullis, P. R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8, 1188-1196 (2001).
28. Bhowmick, S., Ravindran, R. & Ali, N. gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani. Infect Immun 76, 1003-1015 (2008).
29. Feldman, E. J. et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29, 979-985 (2011).
30. Boudreau, J. E., Bonehill, A., Thielemans, K. & Wan, Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 19, 841-853 (2011).
31. n nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano 4, 1178-1186 (2010).
32. Leserman, L. Liposomes as protein carriers in immunology. J Liposome Res 14, 175-189 (2004).
33. Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M. New horizons in adjuvants for vaccine development. Trends Immunol 30, 23-32 (2009).
34. Guy, B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505-517 (2007).
35. Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632 (2007).
36. + T cells. Cell 71, 1205-1214 (1992).
37. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
38. Peachman, K. K. et al. Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens. Immunobiology 210, 321-333 (2005).
39. Homhuan, A., Kogure, K., Nakamura, T., Shastri, N. & Harashima, H. Enhanced antigen presentation and CTL activity by transduction of mature rather than immature dendritic cells with octaarginine-modified liposomes. J Control Release 136, 79-85 (2009).
40. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182, 389-400 (1995).
41. Nakamura, T., Moriguchi, R., Kogure, K., Shastri, N. & Harashima, H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 16, 1507-1514 (2008).
42. Kedzierski, L. Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis 2, 177-185, doi: 10.4103/0974-777X.62881 (2010).
43. Sinha, S., Sundaram, S., Singh, A. P. & Tripathi, A. A gp63 based vaccine candidate against Visceral Leishmaniasis. Bioinformation 5, 320-325 (2011).
44. Cardoso, S. R. et al. Identification and purification of immunogenic proteins from nonliving promastigote polyvalent Leishmania vaccine (Leishvacin). Rev Soc Bras Med Trop 36, 193-199 (2003).
45. Nair, S., Zhou, F., Reddy, R., Huang, L. & Rouse, B. T. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 175, 609-612 (1992).
46. + T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials 30, 910-918 (2009).
47. Steinman, R. M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319-324 (2008).
48. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat Med 19, 1597-1608 (2013).
49. Watts, C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15, 821-850 (1997).
50. Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat Rev Immunol 12, 557-569 (2012).
51. Villadangos, J. A. et al. Proteases involved in MHC dass II antigen presentation. Immunol. Rev. 172, 109-120 (1999).
52. Bryant, P. & Ploegh, H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 16, 96-102 (2004).
53. Mazumder, S., Maji, M., Das, A. & Ali, N. Potency, Efficacy and Durability of DNA/DNA, DNA/Protein and Protein/Protein Based Vaccination Using gp63 Against Leishmania donovani in BALB/c Mice. Plos One 6, doi: 10.1371/journal.pone.0014644 (2011).
54. Lee, K. D., Nir, S. & Papahadjopoulos, D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32, 889-899 (1993).
55. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275 (1951).
56. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176, 1693-1702 (1992).
57. Matheu, M. P., Sen, D., Cahalan, M. D. & Parker, I. Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. J Vis Exp, doi: 10.3791/773 (2008).
58. Mazumdar, T., Anam, K. & Ali, N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22, 1162-1171 (2004).
59. Daleke, D. L., Hong, K. & Papahadjopoulos, D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1024, 352-366 (1990).
60. Straubinger, R. M., Papahadjopoulos, D. & Hong, K. L. Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry 29, 4929-4939 (1990).